Therapeutic delivery最新文献

September 2024 therapeutic delivery: industry update.

IF 3

Therapeutic delivery Pub Date : 2024-12-18 DOI: 10.1080/20415990.2024.2442298

Elaine Harris

引用次数: 0

Topical dutasteride for androgenic alopecia: current state and prospects.

IF 3

Therapeutic delivery Pub Date : 2024-12-06 DOI: 10.1080/20415990.2024.2437973

Jayanaraian F M Andrade, Andrew Verbinnen, Andrew Bakst, Marcílio Cunha-Filho, Guilherme M Gelfuso, Taís Gratieri

引用次数: 0

Cabozantinib-phospholipid complex for enhanced solubility, bioavailability, and reduced toxicity in liver cancer.

IF 3

Therapeutic delivery Pub Date : 2024-11-29 DOI: 10.1080/20415990.2024.2435240

Jayesh Patil, Sankha Bhattacharya, Suprit D Saoji, Payal Dande

{"title":"Cabozantinib-phospholipid complex for enhanced solubility, bioavailability, and reduced toxicity in liver cancer.","authors":"Jayesh Patil, Sankha Bhattacharya, Suprit D Saoji, Payal Dande","doi":"10.1080/20415990.2024.2435240","DOIUrl":"https://doi.org/10.1080/20415990.2024.2435240","url":null,"abstract":"Aims: To enhance the therapeutic potential of Cabozantinib (CBZ), a tyrosine kinase inhibitor with limited water solubility, low bioavailability, and high toxicity, by developing a Cabozantinib-Phospholipid Complex (CBZ-PLS).Materials & methods: CBZ-PLS was formulated using solvent evaporation with a Box-Behnken design and characterized using various techniques to confirm molecular interactions. Solubility, in vitro release, pharmacokinetics, and toxicity were evaluated. Cytotoxic effects on HepG2 cell lines were also assessed.Results: CBZ-PLS exhibited a 126-fold increase in solubility and enhanced CBZ release in vitro. Pharmacokinetic studies on Wistar rats demonstrated a 1.58-fold increase in bioavailability, while acute toxicity studies confirmed biocompatibility. CBZ-PLS showed superior cytotoxicity, apoptosis induction, migration inhibition, increased ROS generation, and greater DNA fragmentation in HepG2 cells. The complex also maintained stability over 6 months.Conclusions: CBZ-PLS significantly improves the solubility, bioavailability, and therapeutic efficacy of CBZ against liver cancer, presenting a promising approach for more effective liver cancer treatment.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"1-17"},"PeriodicalIF":3.0,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142751548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bioinspired caffeic acid-laden milk protein-based nanoparticles targeting folate receptors for breast cancer treatment. 基于生物启发的含咖啡酸牛奶蛋白的纳米颗粒，靶向叶酸受体治疗乳腺癌。

IF 3

Therapeutic delivery Pub Date : 2024-11-26 DOI: 10.1080/20415990.2024.2433938

Sally Safwat, Rania A H Ishak, Rania M Hathout, Nahed D Mortada

{"title":"Bioinspired caffeic acid-laden milk protein-based nanoparticles targeting folate receptors for breast cancer treatment.","authors":"Sally Safwat, Rania A H Ishak, Rania M Hathout, Nahed D Mortada","doi":"10.1080/20415990.2024.2433938","DOIUrl":"https://doi.org/10.1080/20415990.2024.2433938","url":null,"abstract":"Aims: Breast cancer is the second leading cause of death worldwide. Conventional chemotherapeutic therapies lack the specific targeting effect toward the cancerous cells resulting in extensive side effects. Our current study endeavors to prepare novel bioinspired folic acid-functionalized caffeic acid (CA)-loaded casein nanoparticles (CS NPs) for curbing breast cancer.Methods: CA-CS NPs were prepared by simple coacervation method followed by lyophilization. Functionalized CS NPs were achieved using folic acid as the targeting moiety. Entire comparative characterization between unconjugated and conjugated NPs were implemented in terms of size, polydispersity index, surface charge, 1H-NMR, surface morphology, in-vitro drug release, sterilization, cytotoxicity, and animal studies.Results: Conjugated NPs attained PS = 157.23 ± 2.64 nm, PDI = 0.309 ± 0.199, ZP = -25.53 ± 2.31 mV and IC50 = 40 ± 2.9 µg/ml. Significant reduction in the biochemical marker levels of Carcino-embryonic antigen, carbohydrate antigen 15-3, and malondialdehyde while increased superoxide dismutase levels were achieved in the tumor -induced rats treated by the conjugated NPs. Histopathological examinations showed great improvement in the mammary and necrotic regions.Conclusion: The present work paves the road of 'back to nature' approach in designing biocompatible bioinspired conjugated nanocarriers for the diagnosis and treatment of various diseases.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"1-19"},"PeriodicalIF":3.0,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142717068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The simultaneous use of nanovesicles and magnetic nanoparticles for cancer targeting and imaging. 将纳米微粒和磁性纳米微粒同时用于癌症靶向和成像。

IF 3

Therapeutic delivery Pub Date : 2024-11-20 DOI: 10.1080/20415990.2024.2426447

Sara Salatin, Maryam Azarfarin, Afsaneh Farjami, Samin Hamidi

{"title":"The simultaneous use of nanovesicles and magnetic nanoparticles for cancer targeting and imaging.","authors":"Sara Salatin, Maryam Azarfarin, Afsaneh Farjami, Samin Hamidi","doi":"10.1080/20415990.2024.2426447","DOIUrl":"https://doi.org/10.1080/20415990.2024.2426447","url":null,"abstract":"Cancer is increasingly being recognized as a global health issue with considerable unmet medical need. Despite the rapid progression of anticancer pharmaceuticals, there are still significant challenges for the effective management of cancer. In many circumstances, cancer cells are difficult to detect and treat. Combination of nanovesicles (NVs) and magnetic nanoparticles (MNPs), referred as magnetic nanovesicles (MNVs), is now well recognized as a potential theranostic option for improving cancer treatment outcomes and reducing adverse effects. MNVs can be used for monitoring the long-term fate and functional benefits of cancer therapy. Moreover, MNV-mediated hyperthermia mechanism has been explored as a potential technique for triggering cancer cell death, and/or controlled release of laden cargo. In this review, we focus on the unique characteristics of MNVs as a promising avenue for targeted drug delivery, diagnosis, and treatments of cancer or tumor. Moreover, we discuss critical considerations related to the issues raised in this area, which will guide future research toward better anti-cancer therapeutics for clinical applications.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"1-15"},"PeriodicalIF":3.0,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142676905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Phage therapeutic delivery methods and clinical trials for combating clinically relevant pathogens. 抗击临床相关病原体的噬菌体治疗传递方法和临床试验。

IF 3

Therapeutic delivery Pub Date : 2024-11-15 DOI: 10.1080/20415990.2024.2426824

Heba Mohammed Refat M Selim, Fatma Alzahraa M Gomaa, Mohammad Y Alshahrani, Radwa N Morgan, Khaled M Aboshanab

引用次数: 0

Zein decorated rifaximin nanosuspension: approach for sustained release and anti-bacterial efficacy enhancement. Zein 修饰的利福昔明纳米悬浮液：持续释放和提高抗菌功效的方法。

IF 3

Therapeutic delivery Pub Date : 2024-11-12 DOI: 10.1080/20415990.2024.2418799

Atul Mourya, Mayank Handa, Kanchan Singh, Suresh Chintalapati, Jitender Madan, Rahul Shukla

{"title":"Zein decorated rifaximin nanosuspension: approach for sustained release and anti-bacterial efficacy enhancement.","authors":"Atul Mourya, Mayank Handa, Kanchan Singh, Suresh Chintalapati, Jitender Madan, Rahul Shukla","doi":"10.1080/20415990.2024.2418799","DOIUrl":"https://doi.org/10.1080/20415990.2024.2418799","url":null,"abstract":"Aim: The goal of the present work was to formulate zein-decorated rifaximin (RFX) nanosuspension to attain sustained release as well as effectiveness against Escherichia coli (E. coli).Methods: The RFX nanosuspension was fabricated by using antisolvent addition method followed by coating using hydroalcoholic zein solution. The optimized RFX-NS and RFX-NS@zein was lyophilized for further spectroscopic evaluations. In vitro antibacterial potential was elucidated using well diffusion method whereas MIC value was determined by microbroth dilution method against E. coli for RFX-NS and pure RFX.Results: Box-Behnken Design was employed to assess the effects of independent variables on quality target product profile of RFX-NS. Optimized RFX-NS depicted particle size of 193.5 ± 4.45 nm with 76.49 ± 1.71% drug content. The significant change in particle size and zeta potential confirmed the formation of zein coated RFX-NS (RFX-NS@zein). In vitro release study depicted, 96.91 ± 1.21% release of RFX from RFX-NS in 6 h whereas 97.47 ± 1.99% RFX release was observed from RFX-NS@zein at the end of 12 h. Antibacterial assay of RFX-NS and free RFX against E. coli displayed MIC value of 15.44 ± 0.01 μg/ml and 72.96 ± 0.25 μg/ml, respectively.Conclusion: The results highlighted a significance of nanosuspension for improving the solubility of RFX and its antibacterial potential against E. coli.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"1-15"},"PeriodicalIF":3.0,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142628856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Microencapsulation techniques for developing cannabidiol formulations: a review. 用于开发大麻二酚配方的微胶囊技术：综述。

IF 3

Therapeutic delivery Pub Date : 2024-11-12 DOI: 10.1080/20415990.2024.2421155

Ariel Gustavo Garro, Soledad Ravetti, Sofía Gisella Brignone, Agustín Luna, Natalia Angel Villegas, Agustina Gaitán, Santiago Daniel Palma

引用次数: 0

Comprehensive insights into glioblastoma multiforme: drug delivery challenges and multimodal treatment strategies. 全面了解多形性胶质母细胞瘤：给药挑战和多模式治疗策略。

IF 3

Therapeutic delivery Pub Date : 2024-10-24 DOI: 10.1080/20415990.2024.2415281

Ashish Dhiman, Dhwani Rana, Derajram Benival, Kalpna Garkhal

引用次数: 0

Industry Update: the latest developments in the field of therapeutic delivery, July 2024. 行业最新动态：2024 年 7 月治疗给药领域的最新发展。